ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2007;84:2110-2112. doi:10.1016/j.athoracsur.2007.06.064
© 2007 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhagirath, K. M.
Right arrow Articles by Tam, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhagirath, K. M.
Right arrow Articles by Tam, J. W.
Related Collections
Right arrow Congenital - cyanotic

Case Reports

Resolution of Protein-Losing Enteropathy With Low-Molecular Weight Heparin in an Adult Patient With Fontan Palliation

Kapil M. Bhagirath, MD*, James W. Tam, MD, FRCPC

Section of Cardiology, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Accepted for publication June 22, 2007.

* Address correspondence to Dr Bhagirath, c/o Dr Tam, Y3005–409 Tache Ave, Winnipeg, Manitoba, R2H 2A6, Canada (Email: umbhagir{at}cc.umanitoba.ca).

Protein-losing enteropathy is a well-known complication after the Fontan procedure, and unfractionated heparin therapy has been tried with some success as a potential therapy. Low-molecular weight heparin is believed to be ineffective. We now describe a case in which an adult patient with protein-losing enteropathy after Fontan palliation was successfully treated with systemic doses of low-molecular weight heparin, with complete resolution in the 24-hour fecal alpha-1 anti-trypsin level and serum albumin. The patient continues to remain in remission with this therapy. In conclusion, these findings are novel and compel us to re-evaluate our pathophysiologic understanding of this difficult condition.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
D. Thacker, A. Patel, K. Dodds, D. J. Goldberg, E. Semeao, and J. Rychik
Use of Oral Budesonide in the Management of Protein-Losing Enteropathy After the Fontan Operation
Ann. Thorac. Surg., March 1, 2010; 89(3): 837 - 842.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The Society of Thoracic Surgeons.